{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:20Z","timestamp":1794047420651,"version":"4.8.0"},"reference-count":49,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In heterogeneous multiple myeloma (MM) patients treatment decisions are challenging. The hypothesis was that adaptation of treatment intensity (dose reduction [DR] vs. none) according to an objective risk score (revised-myeloma comorbidity index [R-MCI]) rather than physician judgement alone may improve therapy efficacy and avoid toxicities. We performed this study in 250 consecutive MM patients who underwent a prospective fitness assessment at our center, after having received induction protocols based on physicians\u2019 judgement. DR, serious adverse events (SAE), response, progression-free survival (PFS) and overall survival (OS) were compared in fitness (fit, intermediate-fit, frail), age (&lt;60, \u226570 years [y]) and therapy intensity subgroups at baseline and follow-up. Fit and &lt;60 y patients were mostly treated with full intensity, whereas frail and \u226570 y patients usually received DR. Hematological and non-hematological SAE were more frequently seen in frail versus \u226570 y patients. Dose adaptations were mainly necessary in frail patients. OS and PFS were similar in fit and intermediate-fit but significantly worse in frail patients (P=0.0245\/P&lt;0.0001), whereas in age-based subgroups, OS and PFS differences did not reach significance (P=0.1362\/P=0.0569). Non-hematological SAE were another negative predictor for impaired OS and PFS (P=0.0054\/P=0.0021). In the follow-up performed at a median of 11 months after the first fitness assessment, the R-MCI improved or remained stable in 90% versus deteriorated in only 10% of patients. In conclusion, separation by R-MCI\/frailty-defined subgroups was superior to age-based subgroups and can be used to improve tailored treatment. Fitter patients benefit from intensive therapies, whereas frail patients bear a need for initial DR.<\/jats:p>","DOI":"10.3324\/haematol.2022.281489","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T04:50:03Z","timestamp":1667451003000},"page":"1115-1126","source":"Crossref","is-referenced-by-count":11,"title":["An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence"],"prefix":"10.3324","volume":"108","author":[{"given":"Maximilian","family":"Holler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"R\u00f6sner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy-Deborah","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Schoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Scheubeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"46711","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95(5):548-567.","DOI":"10.1002\/ajh.25791"},{"key":"46712","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA. Multiple myeloma. Nat Rev Dis Primer. 2017; 3:17046.","DOI":"10.1038\/nrdp.2017.46"},{"key":"46713","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"46714","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020; 10(2):17.","DOI":"10.1038\/s41408-020-0273-x"},{"key":"46715","doi-asserted-by":"crossref","unstructured":"Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018; 19(6):e305-e316.","DOI":"10.1016\/S1470-2045(18)30348-6"},{"key":"46716","doi-asserted-by":"crossref","unstructured":"Fakhri B, Fiala MA, Tuchman SA, Wildes TM. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. Clin Lymphoma Myeloma Leuk. 2018; 18(3):219-224.","DOI":"10.1016\/j.clml.2018.01.005"},{"key":"46717","doi-asserted-by":"crossref","unstructured":"Goede V, Neuendorff NR, Schulz R-J, Hormigo A-I, Martinez-Peromingo FJ, Cordoba R. Frailty assessment in the care of older people with haematological malignancies. Lancet Healthy Longev. 2021; 2(11):e736-e745.","DOI":"10.1016\/S2666-7568(21)00184-7"},{"key":"46718","doi-asserted-by":"crossref","unstructured":"Scheubeck S, Ihorst G, Schoeller K. Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer. 2021; 127(18):3422-3436.","DOI":"10.1002\/cncr.33658"},{"key":"46719","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.","DOI":"10.1182\/blood.2020005288"},{"key":"46720","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380(22):2104-2115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"46721","doi-asserted-by":"crossref","unstructured":"Bringhen S, Mateos MV, Zweegman S. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98(6):980-987.","DOI":"10.3324\/haematol.2012.075051"},{"key":"46722","doi-asserted-by":"crossref","unstructured":"Klepin HD, Sun C-L, Smith DD. Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy. JCO Oncol Pract. 2021; 17(6):e740-e752.","DOI":"10.1200\/OP.20.00681"},{"key":"46723","doi-asserted-by":"crossref","unstructured":"Terpos E, Engelhardt M, Cook G. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020; 34(8):2000-2011.","DOI":"10.1038\/s41375-020-0876-z"},{"key":"46724","doi-asserted-by":"crossref","unstructured":"Isaacs A, Fiala M, Tuchman S, Wildes TM. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. J Geriatr Oncol. 2020; 11(2):311-315.","DOI":"10.1016\/j.jgo.2019.07.004"},{"key":"46725","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Ihorst G, Duque-Afonso J. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020; 105(5):1183-1188.","DOI":"10.3324\/haematol.2019.242958"},{"key":"46726","doi-asserted-by":"crossref","unstructured":"Palumbo A, Bringhen S, Mateos M-V. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13):2068-2074.","DOI":"10.1182\/blood-2014-12-615187"},{"key":"46727","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Domm A-S, Dold SM. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017; 102(5):910-921.","DOI":"10.3324\/haematol.2016.162693"},{"key":"46728","doi-asserted-by":"crossref","unstructured":"Milani P, Vincent Rajkumar S, Merlini G. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016; 91(11):1129-1134.","DOI":"10.1002\/ajh.24532"},{"key":"46729","doi-asserted-by":"crossref","unstructured":"Cook G, Royle K-L, Pawlyn C. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019; 6(3):e154-e166.","DOI":"10.1016\/S2352-3026(18)30220-5"},{"key":"46730","doi-asserted-by":"crossref","unstructured":"Larocca A, Bonello F, Gaidano G. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021; 137(22):3027-3036.","DOI":"10.1182\/blood.2020009507"},{"key":"46731","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Meuleman N. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020; 34(1):224-233.","DOI":"10.1038\/s41375-019-0539-0"},{"key":"46732","doi-asserted-by":"crossref","unstructured":"Brioli A, Manz K, Pfirrmann M. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2020; 146(3):749-759.","DOI":"10.1007\/s00432-019-03101-z"},{"key":"46733","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Dold SM, Ihorst G. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016; 101(9):1110-1119.","DOI":"10.3324\/haematol.2016.148189"},{"key":"46734","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Mertelsmann R, Duyster J. Das Blaue Buch Chemotherapie-Manual H\u00e4matologie und Onkologie. 7. Auflage. Springer Verlag. 2020.","DOI":"10.1007\/978-3-662-60380-2"},{"key":"46735","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"46736","doi-asserted-by":"crossref","unstructured":"Durie BGM, Harousseau J-L, Miguel JS. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-1473.","DOI":"10.1038\/sj.leu.2404284"},{"key":"46737","doi-asserted-by":"crossref","unstructured":"Greil C, Engelhardt M, Ihorst G. Allogeneic transplantation of multiple myeloma patients may allow longterm survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019; 104(2):370-379.","DOI":"10.3324\/haematol.2018.200881"},{"key":"46738","doi-asserted-by":"crossref","unstructured":"Waldschmidt JM, Keller A, Ihorst G. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I\/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica. 2018; 103(10):e473-e479.","DOI":"10.3324\/haematol.2018.189969"},{"key":"46739","doi-asserted-by":"crossref","unstructured":"Dold SM, M\u00f6ller M-D, Ihorst G. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica. 2021; 106(3):875-880.","DOI":"10.3324\/haematol.2020.254235"},{"key":"46740","doi-asserted-by":"crossref","unstructured":"M\u00f6ller M-D, Ihorst G, Pahl A. Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. J Geriatr Oncol. 2021; 12(4):521-530.","DOI":"10.1016\/j.jgo.2020.11.003"},{"key":"46741","doi-asserted-by":"crossref","unstructured":"Einsele H, Engelhardt M, Tapprich C. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol. 2017; 179(4):586-597.","DOI":"10.1111\/bjh.14920"},{"key":"46742","doi-asserted-by":"crossref","unstructured":"Bachmann F, Schreder M, Engelhardt M. Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM. Cancers. 2021; 13(6):1322.","DOI":"10.3390\/cancers13061322"},{"key":"46743","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309-322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"46744","doi-asserted-by":"crossref","unstructured":"Tuchman SA, Moore JO, DeCastro CD. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (\u201cVCD-Lite\u201d) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. J Geriatr Oncol. 2017; 8(3):165-169.","DOI":"10.1016\/j.jgo.2017.02.004"},{"key":"46745","doi-asserted-by":"crossref","unstructured":"Mai EK, Miah K, Bertsch U. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia. 2021; 35(3):809-822.","DOI":"10.1038\/s41375-020-0976-9"},{"key":"46746","doi-asserted-by":"crossref","unstructured":"Ludwig H, Delforge M, Facon T. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018; 32(7):1542-1560.","DOI":"10.1038\/s41375-018-0040-1"},{"key":"46747","doi-asserted-by":"crossref","unstructured":"Bringhen S, Milan A, Ferri C. Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018; 103(9):1422-1432.","DOI":"10.3324\/haematol.2018.191288"},{"key":"46748","doi-asserted-by":"crossref","unstructured":"Ihne S, Morbach C, Sommer C, Geier A, Knop S, St\u00f6rk S. Amyloidosis - the diagnosis and treatment of an underdiagnosed disease. Dtsch Arzteblatt Int. 2020; 117(10):159-166.","DOI":"10.3238\/arztebl.2020.0159"},{"key":"46749","doi-asserted-by":"crossref","unstructured":"M\u00f6ller M-D, Gengenbach L, Graziani G, Greil C, W\u00e4sch R, Engelhardt M. Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?. Curr Opin Oncol. 2021; 33(6):648-657.","DOI":"10.1097\/CCO.0000000000000792"},{"key":"46750","doi-asserted-by":"crossref","unstructured":"Antoine-Pepeljugoski C, Braunstein MJ. Management of newly diagnosed elderly multiple myeloma patients. Curr Oncol Rep. 2019; 21(7):64.","DOI":"10.1007\/s11912-019-0804-4"},{"key":"46751","doi-asserted-by":"crossref","unstructured":"Cordoba R, Eyre TA, Klepin HD, Wildes TM, Goede V. A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematol. 2021; 8(11):e840-e852.","DOI":"10.1016\/S2352-3026(21)00241-6"},{"key":"46752","doi-asserted-by":"crossref","unstructured":"Rosko AE, Huang Y, Benson DM. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol. 2019; 10(3):479.","DOI":"10.1016\/j.jgo.2018.05.015"},{"key":"46753","doi-asserted-by":"crossref","unstructured":"Soekojo CY, Kumar SK. Stem-cell transplantation in multiple myeloma: how far have we come?. Ther Adv Hematol. 2019; 10:2040620719888111.","DOI":"10.1177\/2040620719888111"},{"key":"46754","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, De Paoli L, Conticello C. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: a pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol. 2018; 132:9-16.","DOI":"10.1016\/j.critrevonc.2018.09.008"},{"key":"46755","doi-asserted-by":"crossref","unstructured":"Stege CAM, Nasserinejad K, Klein SK. Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia. 2021; 35(9):2715-2719.","DOI":"10.1038\/s41375-021-01162-z"},{"key":"46756","doi-asserted-by":"crossref","unstructured":"Cook G, Larocca A, Facon T, Zweegman S, Engelhardt M. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia. 2020; 34(9):2285-2294.","DOI":"10.1038\/s41375-020-0918-6"},{"key":"46757","doi-asserted-by":"crossref","unstructured":"Larocca A, Dold SM, Zweegman S. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018; 32(8):1697-1712.","DOI":"10.1038\/s41375-018-0142-9"},{"key":"46758","doi-asserted-by":"crossref","unstructured":"Stauder R, Eichhorst B, Hamaker ME. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017; 28(2):218-227.","DOI":"10.1093\/annonc\/mdw547"},{"key":"46759","doi-asserted-by":"crossref","unstructured":"Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018; 131(5):515-524.","DOI":"10.1182\/blood-2017-09-746420"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281489\/75012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281489\/75495","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10854\/75012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:42Z","timestamp":1794045762000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281489","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}